Thalidomide for the Treatment of Refractory Multiple Myeloma: Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome
β Scribed by Kakimoto, Tsunayuki ;Hattori, Yutaka ;Okamoto, Shinichiro ;Sato, Norihide ;Kamata, Tamihiro ;Yamaguchi, Masaya ;Morita, Kunihiko ;Yamada, Taketo ;Takayama, Nobuyuki ;Uchida, Hideo ;Shimada, Naoki ;Tanigawara, Yusuke ;Ikeda, Yasuo
- Book ID
- 108582183
- Publisher
- Wiley (Blackwell Publishing)
- Year
- 2002
- Tongue
- English
- Weight
- 139 KB
- Volume
- 93
- Category
- Article
- ISSN
- 0910-5050
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract The aim of the study was the evaluation of antiβangiogenic activity of the combination of intermediate doses of thalidomide and dexamethasone in patients with refractory/relapsed myeloma. Twentyβfive patients were included in the study. Microvessel density (MVD) was evaluated in marrow
Extramedullary relapse constitutes an uncommon manifestation of multiple myeloma (MM), characterized by highly malignant histology, special biological features, resistance to treatment and poor outcome. Its incidence has been increased during the last years, probably due to the introduction of novel